Down-regulation of microRNA-182 and microRNA-183 predicts progression of osteosarcoma

Golbakhsh, Mohammadreza; Boddouhi, Bahram; Hatami, Negin; Goudarzi, Peyman Karimi; Shakeri, Mohammadreza; Yahaghi, Emad; Taheriazam, Afshin

doi:10.5114/aoms.2016.60091

Cited by 12 publications

(15 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…non-coding RNAs (lncRNAs) are frequently deregulated and have critical roles in multiple cancers [4][5][6][7][8][9][10]. These non-coding RNAs could be novel candidates for prognostic biomarkers and therapeutic targets in various cancers including cervical cancer [9][10][11][12][13]. LncRNAs are a class of novel non-coding transcripts with more than 200 nucleotides in length [14,15].…”

mentioning

confidence: 99%

Long non-coding RNA DANCR promotes cervical cancer growth via activation of the Wnt/β-catenin signaling pathway

et al. 2020

View full text Add to dashboard Cite

Background: Long non-coding RNAs (lncRNAs) are implicated in many pathophysiological processes, including cancers. In particular, lncRNA DANCR is regarded as a cancer-associated lncRNA exerting various regulatory mechanisms. However, the expressions, functions, and mechanisms of action of DANCR in cervical cancer are still unclear. Methods: The expressions of DANCR in cervical cancer tissues and cell lines were evaluated using qRT-PCR. Correlations between DANCR expression and clinicopathological features and prognosis were analyzed. The roles of DANCR in cervical cancer growth were evaluated by in vitro CCK-8 and EdU assay, and in vivo xenograft assay. The regulatory effects of DANCR on Wnt/β-catenin signaling pathway were evaluated using nuclear proteins extraction, western blot, and qRT-PCR. Results: DANCR is increased in cervical cancer tissues and cell lines. Increased expression of DANCR is associated with large tumor size, advanced FIGO stage, and poor overall survival of cervical cancer patients. Functional experiments showed that enhanced expression of DANCR promotes cervical cancer cell proliferation in vitro and xenograft growth in vivo. Conversely, DANCR knockdown inhibits cervical cancer cell proliferation in vitro and xenograft growth in vivo. Mechanistic investigation demonstrated that DANCR upregulates the expressions of FRAT1 and FRAT2 and activates the Wnt/β-catenin signaling pathway. Blocking the Wnt/β-catenin signaling pathway abolishes the proproliferative roles of DANCR overexpression and anti-proliferative roles of DANCR knockdown. Conclusions: Our findings suggest DANCR as an oncogenic lncRNA in cervical cancer through activating the Wnt/βcatenin signaling pathway, and imply that DANCR may be a promising prognostic biomarker and therapeutic target for cervical cancer.

show abstract

mentioning

confidence: 99%

Long non-coding RNA DANCR promotes cervical cancer growth via activation of the Wnt/β-catenin signaling pathway

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The results in PCa are supported by studies in breast, lung, and bone cancers in which low expression of miR-182 has been associated with metastasis. 48 , 49 , 50 Conversely, studies in PCa cell lines have found high miR-182 as increasing in vitro and in vivo phenotypes of aggressiveness. 17 , 18 , 20 , 21 Measurement of miR-182 by RT-qPCR in prostate tumor specimens, not microdissected, have found either no significant association 21 , 47 or a positive association of miR-182 expression with recurrence.…”

Section: Discussionmentioning

confidence: 99%

Association of High miR-182 Levels with Low-Risk Prostate Cancer

Baumann

Acosta

Richards

et al. 2019

The American Journal of Pathology

View full text Add to dashboard Cite

A subset of men with prostate cancer develops aggressive disease. We sought to determine whether miR-182, an miRNA with reported oncogenic functions in the prostate, is associated with biochemical recurrence and aggressive disease. Prostate epithelial miR-182 expression was quantified via in situ hybridization of two prostate tissue microarrays and by laser-capture microdissection of prostate epithelium. miR-182 was significantly higher in cancer epithelium than adjacent benign epithelium ( P < 0.0001). The ratio of cancer to benign miR-182 expression per patient was inversely associated with recurrence in a multivariate logistic regression model (odds ratio = 0.18; 95% CI, 0.03–0.89; P = 0.044). Correlation of miR-182 with mRNA expression in laser-capture microdissected benign prostate epithelium was used to predict prostatic miR-182 targets. Genes that were negatively correlated with miR-182 were enriched for its predicted targets and for genes previously identified as up-regulated in prostate cancer metastases. miR-182 expression was also negatively correlated with genes previously identified as up-regulated in primary prostate tumors from African American patients, who are at an increased risk of developing aggressive prostate cancer. Taken together, these results suggest that although miR-182 is expressed at higher levels in localized prostate cancer, its levels are lower in aggressive cancers, suggesting a biphasic role for this miRNA that may be exploited for prognostic and/or therapeutic purposes to reduce prostate cancer progression.

show abstract

“…MicroRNA is a class of small molecule RNA that does not have the ability to encode protein. Micro-RNA has complex physiological functions and participates in the genesis of a variety of complex diseases, including cancers [3][4][5]. MiR-130b was up-regulated and acted as an oncogene in some kinds of cancers [6][7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

Knockdown of microRNA-130b improves doxorubicin sensitivity in bladder urothelial carcinoma by negatively regulating cylindromatosis expression

Zhang

2021

Arch Med Sci

View full text Add to dashboard Cite

Introduction: Chemotherapeutic resistance reduces the sensitivity of bladder urothelial carcinoma (BUC) to chemotherapeutic drugs and contributes a barrier leading to treatment failure. The purpose of this research project is to investigate the regulatory effects of miR-130b on chemotherapeutic drug resistance of BUC and its mechanism. Material and methods: The relative expression of miRNA-130b and cylindromatosis (CYLD) was examined using real-time quantitative PCR. The cell proliferation and doxorubicin sensitivity were detected with the enhanced CCK-8 assay. The specific combination of miR-130b and CYLD was verified with the luciferase reporter gene assay. Protein expression was detected by Western blot. Results: Our study found that miR-130b was up-regulated in doxorubicin-insensitive BUC tissues and cell lines, and its high expression was negatively related to doxorubicin sensitivity in BUC. The miR-130b knockdown reduced the IC 50 of doxorubicin and improved doxorubicin sensitivity of J82/Dox and T24/Dox cells. For the regulation mechanism analysis of miR-130b, bioinformatics analysis software was used to predict the potential targets of miR-130b, including the CYLD gene. The following luciferase activities assay, quantitative real time-PCR and western blot identified the CYLD gene as a target of miR-130b. Knockdown of CYLD reversed miR-130b's regulatory roles in doxorubicin sensitivity in J82/Dox and T24/Dox cells. Conclusions: High expression of miR-130b is negatively related to doxorubicin sensitivity in BUC, and knockdown of miR-130b improves doxorubicin sensitivity in BUC by negatively regulating CYLD expression. Our findings will provide guidance for the clinical chemotherapy of BUC.

show abstract

Down-regulation of microRNA-182 and microRNA-183 predicts progression of osteosarcoma

Cited by 12 publications

References 25 publications

Long non-coding RNA DANCR promotes cervical cancer growth via activation of the Wnt/β-catenin signaling pathway

Long non-coding RNA DANCR promotes cervical cancer growth via activation of the Wnt/β-catenin signaling pathway

Association of High miR-182 Levels with Low-Risk Prostate Cancer

Knockdown of microRNA-130b improves doxorubicin sensitivity in bladder urothelial carcinoma by negatively regulating cylindromatosis expression

Contact Info

Product

Resources

About